tapering < target < targetable

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 62.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000021 (2010)	Nicolas Frey [Suisse] ; Susan Grange [Suisse] ; Thasia Woodworth [Royaume-Uni]	Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
000022 (2011)	Leonid Gibiansky [États-Unis] ; Nicolas Frey [États-Unis]	Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach
000050 (2011)	Masaaki Hiura [Japon] ; Shintaro Abe ; Akinari Tabaru ; Shohei Shimajiri ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Masaru Harada	Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis
000066 (2013)	Kanae Tani [Japon] ; Risa Takayanagi [Japon] ; Haruko Yokoyama [Japon] ; Yasuhiko Yamada [Japon]	Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy
000171 (2015)	Takashi Yamamura [Japon]	Vascular endothelial growth factor: A potential target of therapy in neuromyelitis optica?
000178 (2010)	G. Dückers [Allemagne] ; T. Niehues [Allemagne]	Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still)
000181 (2015)	Yi Zhang [États-Unis] ; Xiaohui Wei [États-Unis] ; Gaurav Bajaj [États-Unis] ; Jeffrey S. Barrett [États-Unis] ; Bernd Meibohm [États-Unis] ; Amita Joshi [États-Unis] ; Manish Gupta [États-Unis]	Challenges and considerations for development of therapeutic proteins in pediatric patients
000194 (2007)	M. Schneider [Allemagne]	Exploring new territory: considering the future
000195 (2010)	Luciana Breda [Italie] ; Marianna Del Torto [Italie] ; Sara De Sanctis [Italie] ; Francesco Chiarelli [Italie]	Biologics in children’s autoimmune disorders: efficacy and safety
000196 (2008)	Y. Shirota [États-Unis] ; Gg Illei [États-Unis] ; Np Nikolov [États-Unis]	Biologic treatments for systemic rheumatic diseases
000206 (2012)	K. Krüger [Allemagne] ; J. Sieper [Allemagne]	Off-Label-Therapie bei rheumatoider Arthritis und Spondyloarthritiden
000230 (2014)	Mo Yin Mok [Hong Kong] ; Debashish Danda [Inde]	‘Treat to target’ for rheumatoid arthritis in 2014 – time tested triple therapy or logical Biologics?
000233 (2010)	Hiroshi Kato [États-Unis] ; David A. Fox [États-Unis]	Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
000246 (2011)	Bernard Bannwarth [France]	Prise en charge thérapeutique de l’inflammation d’origine rhumatismale
000280 (2010)	Valeria Bruno [Italie] ; Giuseppe Battaglia [Italie] ; Ferdinando Nicoletti [Italie]	The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases
000284 (2012)	Usama Elewa [Espagne] ; Maria Dolores Sanchez-Ni O [Espagne] ; Catalina Martin-Cleary [Espagne] ; Beatriz Fernandez-Fernandez [Espagne] ; Jesus Egido [Espagne] ; Alberto Ortiz [Espagne]	Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
000298 (2012)	Yin Liu [États-Unis] ; Yuval Ramot [Israël] ; Antonio Torrelo [Espagne] ; Amy S. Paller [États-Unis] ; Nuo Si [République populaire de Chine] ; Sofia Babay [Israël] ; Peter W. Kim [États-Unis] ; Afzal Sheikh [États-Unis] ; Chyi-Chia Richard Lee [États-Unis] ; Yongqing Chen [États-Unis] ; Angel Vera [Espagne] ; Xue Zhang [République populaire de Chine] ; Raphaela Goldbach-Mansky [États-Unis, Israël] ; Abraham Zlotogorski [Israël]	Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity
000299 (2011)	Nada Kherbeck [France] ; Mathieu C. Tamby [France] ; Guillaume Bussone [France] ; Hanadi Dib [France] ; Frederic Perros [France] ; Marc Humbert [France] ; Luc Mouthon [France]	The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension
000305 (2012)	J. Wollenhaupt [Allemagne] ; K. Krüger [Allemagne]	Frühe und fortgeschrittene rheumatoide Arthritis
000462 (2013)	Reinhard P. T. Rychlik [Allemagne]	Target patient population: how does the regulatory and reimbursement view differ? Insights from the German IQWiG
000464 (2009)	T. Pap [Allemagne]	Aktuelle Trends in Design und Entwicklung monoklonaler Antikörper gegen Entzündungsmediatoren zur Therapie der rheumatoiden Arthritis

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "target" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "target" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    target
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021